Valbonne, France, March 7, 2016 – TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T-cells to treat severe chronic inflammatory and autoimmune diseases, will release on Thursday, March 10, after market closes, its consolidated financial results for the year ended December 31, 2015 and update its strategy and perspectives.
A conference call and webcast will be held on Friday, March 11, at 3:30pm (CET) in English. The conference call will be followed by a Q&A session.
Investors and analysts wishing to participate can access the call via the following teleconferencing number: +33 (0)1 70 77 09 44
The webcast can be followed live online via the link: http://www.anywhereconference.com?UserAudioMode=DATA&Name=&Conference=135299977&PIN=73954371
Following the live call, a replay will be available for 90 days. To listen to the replay, please dial: +33 (0)1 72 00 15 00 / 299977#
About TxCell: www.txcell.com
TxCell is a publicly listed biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe chronic inflammatory and autoimmune diseases with high unmet medical need. TxCell is the only clinical stage cellular therapy company dedicated to the science of regulatory T lymphocytes (Tregs). Tregs are a recently discovered T cell population for which anti-inflammatory properties have been demonstrated. Ovasave(R), TxCell’s lead product candidate, is currently in a phase IIb clinical trial in refractory Crohn’s disease patients. Col-Treg, its second product candidate, for the treatment of autoimmune uveitis, should enter clinical trials in 2016. Based in Sophia-Antipolis, France, TxCell is listed on Euronext Paris and currently has 47 employees.
